T2 Biosystems (TTOO) said Monday it was starting a multi-year distribution agreement with Cardinal Health (CAH), which will exclusively sell its direct-from-blood diagnostics equipment for the rapid detection of sepsis-causing pathogens.
Among the devices included under the new agreements are T2 Biosystems' US Food and Drug Administration-authorized T2Dx Instrument, T2Bacteria Panel and the T2Candida Panel. Financial terms and other details of the new contract were not disclosed.
Price: 111.65, Change: -0.34, Percent Change: -0.30